SC
MRNA icon

Scotia Capital’s Moderna MRNA Stock Holding History

Scotia Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-6,841
Closed -$284K – 900
2024
Q4 		$284K Sell
6,841
-12,735
-65% -$609K ﹤0.01% 717
2024
Q3 		$1.31M Buy
19,576
+6,400
+49% +$588K 0.01% 460
2024
Q2 		$1.56M Sell
13,176
-458
-3% -$58K 0.01% 417
2024
Q1 		$1.45M Buy
13,634
+866
+7% +$87.3K 0.01% 426
2023
Q4 		$1.27M Sell
12,768
-769
-6% -$64.7K 0.01% 424
2023
Q3 		$1.4M Buy
13,537
+5,489
+68% +$612K 0.01% 391
2023
Q2 		$978K Sell
8,048
-9,569
-54% -$1.28M 0.01% 448
2023
Q1 		$2.71M Sell
17,617
-808
-4% -$133K 0.02% 308
2022
Q4 		$3.31M Sell
18,425
-2,765
-13% -$452K 0.03% 278
2022
Q3 		$2.51M Buy
21,190
+56
+0.3% +$8.5K 0.02% 314
2022
Q2 		$3.02M Sell
21,134
-519
-2% -$74.2K 0.02% 298
2022
Q1 		$3.73M Buy
21,653
+13,395
+162% +$2.26M 0.02% 306
2021
Q4 		$2.1M Sell
8,258
-7,045
-46% -$2.06M 0.01% 398
2021
Q3 		$5.89M Buy
15,303
+4,611
+43% +$1.7M 0.04% 223
2021
Q2 		$2.51M Buy
10,692
+5,431
+103% +$971K 0.02% 358
2021
Q1 		$689K Buy
5,261
+2,351
+81% +$341K 0.01% 556
2020
Q4 		$304K Sell
2,910
-2,758
-49% -$279K ﹤0.01% 637
2020
Q3 		$401K Buy
5,668
+1,474
+35% +$103K ﹤0.01% 547
2020
Q2 		$269K Buy
+4,194
New +$230K ﹤0.01% 536

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Scotia Capital's MRNA Position: Q1 2025 in Review

Scotia Capital sold out of Moderna (MRNA) in Q1 2025, closing a stake of 6,841 shares — an estimated $284K sold.

Scotia Capital first reported a position in MRNA in Q2 2020 and held it in 19 quarters. The position peaked at $5.89M in Q3 2021. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Scotia Capital reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Scotia Capital sold 6,841 Moderna shares in Q1 2025, an estimated $284K.
  • Scotia Capital first reported a position in Moderna in Q2 2020 and held it in 19 quarters.
  • Scotia Capital's Moderna position peaked at $5.89M in Q3 2021.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Scotia Capital's 13F filing for Q1 2025, filed 9 May 2025.